Home chmp
 

Keywords :   


Tag: chmp

CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Mercks NOXAFIL (posaconazole)

2014-07-30 14:00:03| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J., July 30, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational intravenous (IV) formulation of NOXAFIL (posaconazole). Language: English read more

Tags: issues positive opinion formulation

 

CHMP Recommends EU Approval Of VIZAMYL (Flutemetamol F18 Injection) For PET Imaging Of Beta Amyloid Plaque

2014-07-02 10:35:13| drugdiscoveryonline Home Page

GE Healthcare recently announced the receipt of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)

Tags: pet beta approval imaging

 
 

PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)

2014-06-04 13:02:23| drugdiscoveryonline News Articles

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older

Tags: positive opinion receives therapeutics

 

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT (vintafolide) and Companion Imaging Agents FOLCEPRI (etarfolatide) and NEOCEPRI (Intravenous (IV) folic acid) in Patients with Platinum-Resistant ...

2014-03-21 13:05:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind. WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT (vintafolide) and Companion Imaging Agents FOLCEPRI (etarfolatide) and NEOCEPRI (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer Language: English Contact: MerckMedia:Ian McConnell, +1 908-423-3046Claire Mulhearn, +1 908-423-7425orInvestors:Carol Ferguson, +1 908-423-4465Justin Holko, +1 908-423-5088orEndocyteMedia:Martina Schwarzkopf, +1 212-845-4292Tony Russo, +1 212-845-4251orInvestors:Stephanie Ascher, +1 212-362-1200 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: ECYT Exchange: NASDAQ read more

Tags: in with positive opinions

 

CHMP Issues Positive Opinion for Tablet Formulation of Merck's NOXAFIL

2014-03-01 00:42:42| Biotech - Topix.net

Merck , known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

Tags: issues positive opinion formulation

 

Sites : [1] [2] [3] [4] next »